AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 29490959
Drug: Adalimumab 40
RxNorm normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab 40 mg every 3 weeks (taper arm)
Trial: 27041257
Drug: Midazolam and
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam and acetaminophen (n = 38)
Trial: 22520863
Drug: Traditional Chinese
RxNorm normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese Medicine (TCM) for AECOPD administered twice daily over 7 to 21 days, followed by TCM for AECOPD-RW over 28 days.
Trial: 10452633
Drug: Itraconazole (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itraconazole (200 mg daily)
Trial: 2198918
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg of oral mifepristone
Trial: 30709391
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual plus activation therapy (AT)
Trial: 28911934
Drug: Dienogest (DNG)
RxNorm normalized name: Dienogest
DrugBank: Dienogest (DB09123)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dienogest (DNG) 2 mg/d, orally for 16 weeks
Trial: 25529904
Drug: Infliximab (TNF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infliximab (TNF antagonist)
Trial: 17424753
Drug: Both drugs
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both drugs (1.5 x ED95)
Trial: 10807113
Drug: Subantimicrobial dose
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subantimicrobial dose doxycycline (SDD) 20 mg bid for 9 months
Trial: 25315126
Drug: Ropivacaine 1.5
RxNorm normalized name: fentanyl-ropivacaine 1.5 mcg/mL-0.2%-NaCl 0.9% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 1.5 mg·ml(‐1), 1 ml·kg(‐1) mixed with 50 mg of magnesium (Group RM)
Trial: 25315126
Drug: Ropivacaine 1.5
RxNorm normalized name: fentanyl-ropivacaine 1.5 mcg/mL-0.2%-NaCl 0.9% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 1.5 mg·ml(‐1), 1 ml·kg(‐1) (Group R)
Trial: 22570185
Drug: Standard single-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard single-dose methotrexate treatment
Trial: 20026785
Drug: Extended-release niacin
RxNorm normalized name: niacin Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release niacin (1500 mg/d)
Trial: 16602327
Drug: Oral antihistamine
RxNorm normalized name: Ahist Antihistamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antihistamine (cetirizine) on demand (group C)
Trial: 7569269
Drug: Pravastatin (HMG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin (HMG CoA reductase inhibitor), dosage and duration not specified
Trial: 2404502
Drug: Extended-release felodipine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release felodipine tablets once daily
Trial: 30379826
Drug: Evocalcet 2
RxNorm normalized name: evocalcet
DrugBank: Evocalcet (DB12388)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Evocalcet 2 mg/day
Trial: 12454315
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (e.g., paclitaxel/trastuzumab or capecitabine/docetaxel)
Trial: 10361111
Drug: Intermediate serum
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermediate serum hyaluronan (HYA) values (10 to 120 micrograms/L)
Trial: 10361111
Drug: Abnormally low
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abnormally low HYA values (0 to 9 micrograms/L)
Trial: 10361111
Drug: High HYA
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High HYA values (>120 micrograms/L)
Trial: 2405628
Drug: Low-dose warfarin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose warfarin (average daily dose of 4.6 mg)
Trial: 19226611
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy and hypnosis (CBTH)
Trial: 18004255
Drug: TIKLO (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TIKLO (250 mg, BID)
Trial: 18004255
Drug: Thrombo ASS
RxNorm normalized name: thrombin
DrugBank: Thrombin (DB11300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombo ASS (100 mg, QD)
Trial: 7914611
Drug: 300 mg/day
RxNorm normalized name: alpelisib 300 mg/day (150 mg x 2) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg/day amiodarone
Trial: 23510493
Drug: Amlodipine 5
RxNorm normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine 5 mg for 6 weeks, then increased to 10 mg till week 12, then hydrochlorothiazide 25 mg added
Trial: 23510493
Drug: Hydrochlorothiazide 25
RxNorm normalized name: hydrochlorothiazide 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide 25 mg till week 6, then amlodipine 5‐10 mg added
Trial: 11690571
Drug: Plasma fibrinogen
RxNorm normalized name: fibrinogen
DrugBank: Fibrinogen human (DB09222)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma fibrinogen levels (baseline <314 mg/dL)
Trial: 11690571
Drug: Plasma fibrinogen
RxNorm normalized name: fibrinogen
DrugBank: Fibrinogen human (DB09222)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma fibrinogen levels (314 to 373 mg/dL)
Trial: 11690571
Drug: Plasma fibrinogen
RxNorm normalized name: fibrinogen
DrugBank: Fibrinogen human (DB09222)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma fibrinogen levels (>373 mg/dL)
Trial: 11690571
Drug: Upper tertile
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Upper tertile of fibrinogen levels (>373 mg/dL)
Trial: 7875187
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate extended-release (ISDN-ER) 10 mg immediate release and 60 mg slow release
Trial: 7875187
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate extended-release (ISDN-ER)
Trial: 8477320
Drug: Antibiotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic treatment only for reflux grade III or less
Trial: 1868479
Drug: Surgery plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgery plus antibiotic treatment for reflux grade IV
Trial: 8477320
Drug: Antibiotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic treatment alone for reflux grade IV
Trial: 23676933
Drug: Oxcarbazepine (OXC)
RxNorm normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxcarbazepine (OXC) suspension
Trial: 17711537
Drug: Carbamazepine (CBZ)
RxNorm normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carbamazepine (CBZ) tablets
Trial: 20233196
Drug: S-0139 (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-0139 (15 μg kg-1 min-1)
Trial: 20233196
Drug: S-0139 (15.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-0139 (15.7 μg kg-1 min-1) in delayed administration study
Trial: 20233196
Drug: S-0139 (0.08-13.33
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-0139 (0.08-13.33 μg kg-1 min-1) in pilot study
Trial: 16496208
Drug: Double IUI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double IUI (two inseminations 18-24 and 36-48 hours post hCG injection)
Trial: 16496208
Drug: Single IUI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single IUI (one insemination 34 hours post hCG administration)
Trial: 11224838
Drug: Individualized homeopathic
RxNorm normalized name: Urtica urens homeopathic preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized homeopathic medicine
Trial: 1695783
Drug: Nonsurgical or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonsurgical or surgical treatment for BPH
Trial: 324177
Drug: Live dysentery
RxNorm normalized name: fecal microbiota, live Enema [Rebyota]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live dysentery Sonne vaccine (3 to 25 milliard live microbial cells, single and triple immunization schemes)
Trial: 324177
Drug: Live dysentery
RxNorm normalized name: fecal microbiota, live Enema [Rebyota]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live dysentery Sonne vaccine
Trial: 12188171
Drug: Topical glaucoma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical glaucoma medications
Trial: 25557395
Drug: Emotion Regulation
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Emotion Regulation Group Therapy (ERGT)
Trial: 7926139
Drug: 1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/kg locally
Trial: 3617193
Drug: Combined supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined supplement of iron, thiamine, riboflavin, and vitamin C for 3 months
Trial: 28842994
Drug: Preservative- and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preservative- and adjuvant-free trivalent split vaccine
Trial: 1859751
Drug: Neostigmine 0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine 0.05 mg kg‐1
Trial: 22638811
Drug: d-amphetamine 40
RxNorm normalized name: amphetamine / dextroamphetamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d-amphetamine 40 mg
Trial: 22638811
Drug: d-amphetamine (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d-amphetamine (both doses)
Trial: 12459402
Drug: Lead chelation
RxNorm normalized name: lead
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lead chelation therapy
Trial: 7954994
Drug: Midazolam loading
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam loading dose of 0.03 mg.kg-1 and infusion rate of 0.5 micrograms.kg-1.min-1
Trial: 26724628
Drug: Combined EVD
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined EVD and Ommaya reservoir with urokinase (20,000 IU/dose)
Trial: 19294387
Drug: CI-1033 50
RxNorm normalized name: CI 77266
DrugBank: Carbon black (DB11980)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CI-1033 50 mg daily (arm A)
Trial: 15563362
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg ketoconazole administered orally every 24 h for 29 days
Trial: 12035596
Drug: Brinzolamide in
RxNorm normalized name: Product containing brinzolamide in ocular dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brinzolamide in combination with other therapies
Trial: 3310629
Drug: Sucralfate (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucralfate (1 g three times a day one‐half hour before meals for four weeks)
Trial: 25016780
Drug: IL-6 serum
RxNorm normalized name: IL-6
DrugBank: Human interleukin-6 (DB15060)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL-6 serum level in patients with colon adenomas (19.80 +/- 7.44 pg/ml)
Trial: 7559897
Drug: GnRH analog
RxNorm normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GnRH analog (Buserelin) in combination with cyproterone acetate (Androcur); n = 23
Trial: 17353513
Drug: Aliskiren (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aliskiren (150 mg) + HCTZ (25 mg)
Trial: 17353513
Drug: Irbesartan (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irbesartan (150 mg) + HCTZ (25 mg)
Trial: 7755647
Drug: Gemfibrozil treatment
RxNorm normalized name: Gemfibrozil
DrugBank: Gemfibrozil (DB01241)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gemfibrozil treatment
Trial: 8582390
Drug: Beta-blocker (acebutalol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blocker (acebutalol or atenolol)
Trial: 219509
Drug: timolol-hydrochlorothiazide-amiloride combination
RxNorm normalized name: amiloride / hydrochlorothiazide / timolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: timolol-hydrochlorothiazide-amiloride combination
Trial: 219509
Drug: beta-blocker (timolol)
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: beta-blocker (timolol) alone
Trial: 219509
Drug: combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: combination of two diuretics (hydrochlorothiazide + amiloride)
Trial: 1979634
Drug: beta-blocker/diuretic combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: beta-blocker/diuretic combination
Trial: 12960909
Drug: Dalteparin (5000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalteparin (5000 IU subcutaneously once daily)
Trial: 12960909
Drug: Enoxaparin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin (30 mg subcutaneously every 12 hr)
Trial: 2061445
Drug: Topical 10%
RxNorm normalized name: urea topical 10% topical cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 10% cyclosporine in oily solution
Trial: 2061445
Drug: Intravenous thymopentin
RxNorm normalized name: thymopentin
DrugBank: Thymopentin (DB11996)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous thymopentin
Trial: 6352005
Drug: prednimustine intermittently;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: prednimustine intermittently; 160 mg/m2 d 1 to 5, repeated every three weeks
Trial: 6352005
Drug: chlorambucil 8
RxNorm normalized name: Chlorambucil
DrugBank: Chlorambucil (DB00291)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: chlorambucil 8 mg/m2 d plus prednisolone 8 mg/m2 d, both given continuously
Trial: 30851006
Drug: Self-managed titration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-managed titration of Gla-300
Trial: 26601770
Drug: Autonomic regulation
RxNorm normalized name: AUTONOMIC MEDICATIONS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autonomic regulation therapy (ART) with chronic vagus nerve stimulation
Trial: 17506903
Drug: Supervised, weekly,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised, weekly, hospital-based exercise
Trial: 1716558
Drug: Scopolamine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scopolamine (3 doses)
Trial: 29560570
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral tablets
Trial: 24876619
Drug: Oral hepatic-directed
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral hepatic-directed vesicle-insulin (HDV-I) 0.05 U/kg
Trial: 24876619
Drug: Oral hepatic-directed
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral hepatic-directed vesicle-insulin (HDV-I) 0.1 U/kg
Trial: 24876619
Drug: Oral hepatic-directed
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral hepatic-directed vesicle-insulin (HDV-I) 0.2 U/kg
Trial: 24876619
Drug: Oral hepatic-directed
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral hepatic-directed vesicle-insulin (HDV-I) 0.4 U/kg
Trial: 10547079
Drug: Losartan, 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan, 75 mg/day
Trial: 9857880
Drug: Continuous transdermal
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous transdermal GTN, 0.6 mg/h
Trial: 1855357
Drug: 10 mg/day
RxNorm normalized name: Adlarity 10 MG/Day Weekly Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/day enalapril
Trial: 1855357
Drug: 20 mg/day
RxNorm normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/day enalapril
Trial: 6185553
Drug: Cromolyn 2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cromolyn 2% (nonirritant dose)
Trial: 31602822
Drug: Sodium citrate
RxNorm normalized name: Sodium Citrate
DrugBank: Sodium nitrate (DB15952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium citrate in capsules (500 mg·kg‐1 body mass)
Trial: 26748056
Drug: Implant removal
RxNorm normalized name: Super Spot Remover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implant removal surgeries
Trial: 24281290
Drug: Epidural racemic
RxNorm normalized name: EPINEPHRINE,RACEMIC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural racemic ketamine 0.5 mg/kg preincisional +0.25 mg/kg/h for 48 h
Trial: 3996172
Drug: Social skills
RxNorm normalized name: Safety 1st Social Safety Pack KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Social skills intervention group (daily social-learning exercises)
Trial: 15825529
Drug: 0.9% sodium
RxNorm normalized name: LMD with 0.9% Sodium Chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% sodium chloride ophthalmic solution, one instillation four times daily for 21 days
Trial: 10506606
Drug: DepoCyt 50
RxNorm normalized name: DepoCyt 50 MG in 5 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DepoCyt 50 mg once every 2 weeks
Trial: 10506606
Drug: Free ara-C
RxNorm normalized name: cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Free ara-C 50 mg twice a week for 1 month
Trial: 8894655
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (Heparin)
Trial: 2852903
Drug: Nedocromil sodium
RxNorm normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nedocromil sodium 2 mg
Trial: 30070742
Drug: Peppermint oil
RxNorm normalized name: Peppermint Oil
DrugBank: Peppermint oil (DB11198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peppermint oil capsules (menthol)
Trial: 27196485
Drug: Nefopam (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nefopam (20 mg administered before surgery)
Trial: 23583433
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg eluxadoline
Trial: 23583433
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg eluxadoline
Trial: 23583433
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg eluxadoline
Trial: 21916043
Drug: Ultragrivac vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultragrivac vaccine with 21 day interval
Trial: 11298665
Drug: Almotriptan 12.5
RxNorm normalized name: almotriptan 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Almotriptan 12.5 mg on day 7 with propranolol 80 mg twice daily for 7 days
Trial: 10674661
Drug: Whole cell/recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole cell/recombinant B subunit cholera vaccine
Trial: 8697924
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose aspirin (ASA, 50mg/day) for more than two weeks
Trial: 786671
Drug: Indoprofen (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indoprofen (up to 400 mg)
Trial: 28445790
Drug: Nurse-led group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nurse-led group treatment for insomnia based on cognitive behavioral therapy techniques; 2 days of training for nurses.
Trial: 23720354
Drug: Multi-agent chemotherapy
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-agent chemotherapy including high dose methotrexate, Ara-C, and intrathecal treatment
Trial: 18385263
Drug: Methylergometrine (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylergometrine (0.2 mg i.v.)
Trial: 23839254
Drug: Chorionic membrane
RxNorm normalized name: Chorionic Gonadotropin
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chorionic membrane (CM) with periodontal pocket therapy
Trial: 23839254
Drug: Periodontal pocket
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Periodontal pocket therapy alone (Control)
Trial: 22300693
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid (UDCA) 500 mg twice daily for 4 weeks
Trial: 19088307
Drug: Control formula
RxNorm normalized name: Anti Acne Control Formula Top
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control formula supplemented with PDX, GOS, and lactulose (4 g/liter) (PGL4 group; n = 27)
Trial: 19088307
Drug: Control formula
RxNorm normalized name: Anti Acne Control Formula Top
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control formula supplemented with PDX, GOS, and lactulose (8 g/liter) (PGL8 group; n = 25)
Trial: 17169532
Drug: Single low-level
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single low-level systemic hyperthermia treatment in scleroderma patients (n=46)
Trial: 7639162
Drug: RV‐>patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RV‐>patch
Trial: 7639162
Drug: RV‐>patch +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RV‐>patch + SVC
Trial: 7027430
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g of salsalate